Gynecologic Oncology Reports最新文献

{"title":"The use of near-infrared angiography in evaluating bowel anastomosis during a gynecologic oncology surgery","authors":"Lea A. Moukarzel ,&nbsp;Sarah Andres ,&nbsp;Oliver Zivanovic","doi":"10.1016/j.gore.2024.101474","DOIUrl":"10.1016/j.gore.2024.101474","url":null,"abstract":"<div><p>Reducing anastomotic leak rates after bowel resection is a priority among patients undergoing gynecologic oncology surgery. While near-infrared (NIR) angiography has been investigated in the colorectal literature, more recent work has demonstrated promising results when used in gynecologic cancer surgery. It has been repeatedly shown to be a safe intervention that can offer real time assessment of bowel perfusion, offering the surgeon the opportunity to act on the results in the hopes of decreasing the risk of complications.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S235257892400153X/pdfft?md5=0c6591c82c6254af6a826854670b6575&pid=1-s2.0-S235257892400153X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study","authors":"Swapna Kochuveettil ,&nbsp;Roberto Angeli Morales ,&nbsp;Alicja Kaminska ,&nbsp;Gerardo Colon-Otero","doi":"10.1016/j.gore.2024.101475","DOIUrl":"10.1016/j.gore.2024.101475","url":null,"abstract":"<div><p>The goal of this study was to assess the safety of nab-paclitaxel in patients with ovarian cancer or endometrial cancer who had an allergic reaction to paclitaxel. We performed a retrospective review of patients with endometrial cancer or ovarian cancer with an allergic reaction to paclitaxel who were subsequently treated with nab-paclitaxel at the Mayo Clinic Florida from January 2016 to June 2023. A total of 43 patients with ovarian cancer (31) or endometrial cancer (12) and a paclitaxel allergic reaction were identified. All patients were pre-medicated against allergic reactions prior to paclitaxel and subsequent nab-paclitaxel. Allergic reactions to paclitaxel were mild in fourteen patients (33%), moderate in twenty-five patients (58%) and severe in four (9%) patients. None of the 43 patients had an allergic reaction to subsequent nab-paclitaxel. Our data suggests that the administration of nab-paclitaxel to endometrial cancer or ovarian cancer patients with allergic reactions to paclitaxel is safe and should be considered a preferable treatment option in this clinical situation.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001541/pdfft?md5=f7addfccbc14a0e022c6d69b19ead9b8&pid=1-s2.0-S2352578924001541-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141962953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between metabolic syndrome and cervical cancer among women in Southwestern Uganda: A case-control study","authors":"Rogers Kajabwangu ,&nbsp;Joseph Ngonzi ,&nbsp;Jonathan Izudi ,&nbsp;Joel Bazira ,&nbsp;Frank Ssedyabane ,&nbsp;Michael Kanyesigye ,&nbsp;Raymond Atwine ,&nbsp;Musa Kayondo ,&nbsp;Rogers Ankunda ,&nbsp;Henry Mark Lugobe ,&nbsp;Stuart Turanzomwe ,&nbsp;Thomas C. Randall ,&nbsp;Francis Bajunirwe","doi":"10.1016/j.gore.2024.101465","DOIUrl":"10.1016/j.gore.2024.101465","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the association between MetS and its components with cervical cancer among women in South-western Uganda.</p></div><div><h3>Methods</h3><p>We conducted an unmatched case-control study on 470 participants in a 1:2 case-to-control ratio among women in southwestern Uganda. We recruited 157 women with cervical cancer as cases and 313 women without cervical cancer as controls at the Mbarara Regional Referral Hospital Cervical Cancer Clinic. We assessed for MetS using the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) criteria. We used a multivariable binary logistic regression analysis to determine the association between MetS and its components with cervical cancer adjusted for potential confounders. We reported the adjusted odds ratios (aOR) and 95% confidence intervals (CI).</p></div><div><h3>Results</h3><p>Cases were significantly older than controls: 52.4 ± 13.15 versus 41.9 ± 11.9 respectively, p &lt; 0.001. We found MetS was independently associated with cervical cancer (aOR 1.66; 95 % CI 1.07–2.57). Age ≥ 50 years (aOR-2.20; 95 % CI 1.35–3.56), HIV infection (aOR 2.51, 95 % CI 1.56–4.05), increasing parity (aOR 1.16, 95 % CI 1.06–1.26), and a lack of formal education (aOR 6.41, 95 % CI, 1.33–30.86) were also associated with cervical cancer. However, none of the components of MetS was associated with cervical cancer.</p></div><div><h3>Conclusion</h3><p>In Ugandan women, MetS was associated with a higher likelihood of cervical cancer. We, therefore recommend combined screening for MetS and cervical cancer in order to reduce morbidity and mortality from both Mets and cervical cancer.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001449/pdfft?md5=cac086d864851f65112fdc2655fa2818&pid=1-s2.0-S2352578924001449-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary cytoreduction in recurrent ovarian cancer- experience from a tertiary care centre in India","authors":"Priya Bhati,&nbsp;Anitha Thomas,&nbsp;Rachel George Chandy,&nbsp;Amrita Datta,&nbsp;Dhanya Susan Thomas,&nbsp;Vinotha Thomas,&nbsp;Abraham Peedicayil,&nbsp;Ajit Sebastian","doi":"10.1016/j.gore.2024.101463","DOIUrl":"10.1016/j.gore.2024.101463","url":null,"abstract":"<div><h3>Introduction</h3><p>Ovarian cancer is a disease that presents in advanced stage, due to the absence of any specific or overtly dramatic symptoms. The standard of care is primary debulking surgery, followed by chemotherapy. Ovarian cancer recurrence treatment is very challenging and there is always a debate between cytoreduction vs chemotherapy.</p></div><div><h3>Methods</h3><p>The electronic medical records of all patients who underwent secondary cytoreductive surgery for recurrent ovarian cancer between January 2011 and December 2019 were retrieved the patients with platinum sensitive recurrent ovarian cancer who underwent secondary cytoreductive surgery in our department during this time period were included.</p></div><div><h3>Results</h3><p>A total of 52 patients underwent secondary cytoreductive surgery for recurrent ovarian cancer during the study period. Median treatment free interval after primary treatment was 20 months (range 6–132). The secondary cytoreductive surgery was highly complex in 4(8 %) patients,19 (37 %) had intermediate surgical complexity score, 29 (55 %) had low surgical complexity score according to the Aletti complexity score. Secondary cytoreductive surgery was complete (no macroscopic residual disease) in 31(60 %); Optimal (R1) in 17 (33 %) and suboptimal in only 4 (7 %) of the patients. Out of the 52 patients,8 expired, 16 had a second recurrence, and 10 were lost to follow up over time.</p></div><div><h3>Conclusion</h3><p>Successful surgery is possible in well selected patients, which in turn can lead to a meaningful progression free and overall survival benefit. Meticulous individualisation of cases should be done keeping in mind the patient’s performance status, prior treatment history &amp; toxicity; distribution &amp; extent of disease, and the patient’s overall life goals.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001425/pdfft?md5=5b48018260222633c652d94255aa496c&pid=1-s2.0-S2352578924001425-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141960671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From knowledge to advocacy: Bridging the gap between research and action","authors":"Evelyn A. Reynolds,&nbsp;Shariska P. Harrington,&nbsp;Jamie N. Bakkum-Gamez","doi":"10.1016/j.gore.2024.101461","DOIUrl":"10.1016/j.gore.2024.101461","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001401/pdfft?md5=e3cddf2c259d302090c6b050646b9c7a&pid=1-s2.0-S2352578924001401-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141705354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvo-vaginal stromal tumours – Case series of a rare entity from an oncology centre in India","authors":"Biswajit Dash ,&nbsp;Sushmita Rath ,&nbsp;Bharat Rekhi ,&nbsp;Neha Mittal ,&nbsp;Rohini Kulkarni ,&nbsp;T.S. Shylasree ,&nbsp;Amita Maheshwari","doi":"10.1016/j.gore.2024.101464","DOIUrl":"10.1016/j.gore.2024.101464","url":null,"abstract":"<div><p>Vulvo-vaginal stromal tumours are a rare and diverse group of mesenchymal neoplasms unique to hormone-responsive stroma of the vulva and vagina. These tumours are mostly benign, except for the locally aggressive deep angiomyxomas. Often these tumours pose diagnostic challenges, resembling certain malignant vulvo vaginal tumours.</p><p>This case series highlights clinicopathological features of four angiomyxomas; a single angiomyofibroblastoma, and another superficial myofibroblastoma, including their clinical outcomes. All patients were in their 4th or 5th decade of life. Only 1/4 angiomyxomas was correctly diagnosed at the referring hospitals. Three out of four patients harbouring angiomyxomas achieved clinical remission post-surgery, while one patient was lost to follow-up. By immunohistochemistry, tumor cells showed variable positivity for desmin, SMA, ER, and PR, and negativity for S100P and CD34. The angiomyofibroblastoma was initially misdiagnosed as a liposarcoma, and the patient was lost to follow-up after diagnosis. Immunohistochemically, the tumor cells were diffusely positive for SMA and ER; weakly and focally positive for desmin, and negative for AE1/AE3, CD34, and S100P. The patient with superficial myofibroblastoma is in clinical remission post-excision with an 18-month follow-up. Immunohistochemically, the tumor cells showed CD34 positivity. Therapeutically, none of the patient received adjuvant treatment, except for a single patient with angiomyxoma, who underwent chemoradiation for a synchronous cancer cervix post-surgery.</p><p>This case series provides valuable insights into the clinical heterogeneity, diagnostic intricacies, and outcomes of vulvo-vaginal stromal tumours from an oncology centre in India, further contributing to a better understanding of these rare tumours.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001437/pdfft?md5=dc998b3fca10262450d407a403e2512b&pid=1-s2.0-S2352578924001437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141847034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uterine preservation in low-grade endometrial stromal sarcoma","authors":"Shalini Rajaram ,&nbsp;Lakhwinder Singh ,&nbsp;Ayush Heda ,&nbsp;Latika Chawla ,&nbsp;Ravi Hari Phulware ,&nbsp;Ashok Singh ,&nbsp;Simardeep Kaur","doi":"10.1016/j.gore.2024.101470","DOIUrl":"10.1016/j.gore.2024.101470","url":null,"abstract":"<div><p>Data on uterine preservation in the management of low grade endometrial stromal sarcoma (LGESS) is scarce due to rarity of this tumor type. Standard management of LGESS involves extrafascial hysterectomy with bilateral salpingo-oophorectomy with debulking of any extrauterine metastatic disease. High estrogen and progesterone receptor expression facilitates adjuvant hormone therapy post-surgery. LGESS frequently affects young women, thus fertility preservation is an important issue in management. Here we describe uterine preservation in two young women diagnosed with LGESS followed by GnRH analogue therapy with favorable outcome. The first case was diagnosed with recurrent endometrial polyp invading myometrium requiring wedge resection of uterus with free margins. Second case presented with a vaginal mass arising from cervix and excision was done through vaginal route. Both patients were prescribed GnRH analogue therapy for six months post-surgery and are currently on follow-up. These case reports add to literature on feasibility of uterine preservation in the management of LGESS.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001498/pdfft?md5=eadfe6fb16543c96ee8c84f0a9d88107&pid=1-s2.0-S2352578924001498-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141841561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant radiotherapy followed by hysterectomy in locally advanced endometrial cancer: Outcomes from a tertiary government hospital in the Philippines","authors":"John Michael P. Tomagan ,&nbsp;Charles Cedy C. Lo ,&nbsp;Alyssa Anne E. Granda ,&nbsp;Mae M. Panaligan ,&nbsp;Candice Chin-Chin C. Yu ,&nbsp;Veronica T. Vera Cruz","doi":"10.1016/j.gore.2024.101469","DOIUrl":"10.1016/j.gore.2024.101469","url":null,"abstract":"<div><h3>Objective</h3><p>Managing endometrial cancer with suspected or gross cervical involvement lacks a standard approach. This study evaluated outcomes in patients with cervical and/or parametrial involvement treated with neoadjuvant radiation followed by hysterectomy.</p></div><div><h3>Methods</h3><p>Fourteen patients from 2007 to 2022 with locally advanced endometrial cancer and cervical and/or parametrial involvement were retrospectively analyzed. They received neoadjuvant external beam radiotherapy (45–50.4 Gy in 25–30 fractions) and high-dose rate brachytherapy (5.5–7.0 Gy per fraction in 3–4 fractions), followed by extrafascial hysterectomy. Clinical data, pathologic response, and survival outcomes were assessed, along with factors associated with pathologic response.</p></div><div><h3>Results</h3><p>Most patients (86%) had stage III disease with cervical extension, 93% had parametrial involvement, and 14% had nodal involvement. Chemotherapy was given to 86% either concurrently or adjuvantly. Post-surgery, 86% had no pathologic cervical involvement, and 93% had negative surgical margins. Pathologic complete response was seen in 43%. Locoregional recurrence occurred in 14%. Median follow-up was 30 months, with recurrence-free survival and overall survival rates of 86% and 100%, respectively. Lower grade tumors significantly correlated with pathologic complete response (Φ = 0.72, p = 0.026). No significant correlation was found between pathologic complete response and other factors. No late grade 3–4 toxicities were reported.</p></div><div><h3>Conclusion</h3><p>Neoadjuvant radiation followed by hysterectomy, with or without chemotherapy, is a viable strategy for managing endometrial cancer with cervical and/or parametrial involvement. This approach enhances resectability, yielding high rates of pathologic complete response and negative resection margins, showing promise for this challenging patient group.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001486/pdfft?md5=a3f8a025d1cb83440ad6d393552333ea&pid=1-s2.0-S2352578924001486-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endometrial cancer recurrence after the use of a uterine manipulator during laparoscopic surgery","authors":"Jessica M. Souza ,&nbsp;Kristen Stearns ,&nbsp;Fang-Chi Hsu ,&nbsp;Laurel K. Berry ,&nbsp;Michael G. Kelly ,&nbsp;Janelle P. Darby","doi":"10.1016/j.gore.2024.101468","DOIUrl":"10.1016/j.gore.2024.101468","url":null,"abstract":"<div><h3>Objective</h3><p>Minimally invasive surgery (MIS) is the standard approach for the staging and treatment of early-stage endometrial cancer (EC) and often includes use of a uterine manipulator. Uterine perforation is a known risk in this setting, and the impact of perforation and tumor spillage on cancer recurrence is largely unknown. The aim of this study was to assess the association between uterine perforation and/or tumor spillage at the time of MIS for low-grade, early-stage EC on disease recurrence.</p></div><div><h3>Methods</h3><p>A retrospective single-center cohort study was conducted including patients who underwent MIS for management of low-grade and early-stage EC with use of a uterine manipulator. Rates of disease recurrence were compared between patients with and without documented uterine perforation and/or tumor spillage at the time of surgery. Statistical significance was defined as p &lt; 0.05.</p></div><div><h3>Results</h3><p>408 patients with low-grade and early-stage EC were identified from the tumor registry and included in the study. Uterine perforation and/or tumor spillage was documented in 5.9 % (24/408) of cases. Recurrent disease was noted in 8.1 % (33/408) of the entire cohort. Most patients had isolated local recurrence (23/33; 69.7 %), while 9.1 % (3/33) had distant recurrence and 21.2 % (7/33) had both local and distant recurrence. There was no association between uterine perforation and/or tumor spillage and recurrence rates (p = 0.67). The trend in disease free survival was shorter among patients with these complications.</p></div><div><h3>Conclusions</h3><p>Our analysis did not demonstrate a statistically significant difference in disease recurrence rates among patients with early-stage, low-grade EC based on uterine perforation and/or tumor spillage at the time of surgery.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001474/pdfft?md5=138f90e8533ea2ec67fc3b2596b85efc&pid=1-s2.0-S2352578924001474-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FOXP3 serum concentration; a likely predictor of CIN and cervical cancer: Secondary analysis from a case control study at a clinic in South western Uganda","authors":"Frank Ssedyabane ,&nbsp;Nixon Niyonzima ,&nbsp;Joseph Ngonzi ,&nbsp;Josephine Nambi Najjuma ,&nbsp;Hope Mudondo ,&nbsp;Christopher Okeny ,&nbsp;Doreen Nuwashaba ,&nbsp;Deusdedit Tusubira","doi":"10.1016/j.gore.2024.101466","DOIUrl":"10.1016/j.gore.2024.101466","url":null,"abstract":"<div><p>Biomarkers including Forkhead/winged-helix transcription factor box P3 have been proposed in immunohistochemical techniques to diagnose cervical lesions, but can be objectively quantified and measured in blood using methods that can be standardised. In this study we quantified the serum FOXP3 concentrations and assessed their association with cervical lesions at the cervical cancer clinic of Mbarara Regional Hospital (MRRH) Southwestern Uganda.</p><p>We performed secondary analysis on archived serum samples from a previous unmatched case control study in which we recruited 90 cervical cancer (CC) cases, 90 cervical intraepithelial neoplasia (CIN) cases before any form of treatment and 90 controls. Clinical and demographic data were recorded. We measured FOXP3 concentrations using quantitative ELISA. We performed descriptive statistics and logistic regression in STATA 17 and took P-values of &lt; 0.05 as statistically significant.</p><p>The mean concentration of FOXP3 was higher in serum samples from CC cases compared with CIN cases and controls, and this difference was statistically significant (P value &lt; 0.001). More than half (52/90,58 %) of serum samples from CC cases had FOXP3 concentrations greater than 0.0545 ng/ml (P value &lt; 0.001). Increase serum FOXP3 expression was not associated with CIN. Increase in serum FOXP3 concentrations were observed to increase the chances of CC by 2 times (OR: 2.094, P value 0.038, 95 % CI: 1.042–––4.209).</p><p>Serum FOXP3 is likely associated with cervical lesions especially CC in our study population. Serum FOXP3 testing may be useful in resource limited settings to aid detection of such lesions given the challenges associated with cytology and VIA. We recommend diagnostic utility studies for circulating FOXP3 as a biomarker for detection of cervical cancer.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001450/pdfft?md5=3b082246090991fff3b2d4c2a26ee0de&pid=1-s2.0-S2352578924001450-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}